RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ono Pharmaceutical Co Stock

Ono Pharmaceutical Co Equity 2024

Ono Pharmaceutical Co Equity

792.96 B JPY

Ticker

4528.T

ISIN

JP3197600004

WKN

859650

In 2024, Ono Pharmaceutical Co's equity was 792.96 B JPY, a 20.9% increase from the 655.91 B JPY equity in the previous year.

Ono Pharmaceutical Co Aktienanalyse

What does Ono Pharmaceutical Co do?

Ono Pharmaceutical Co Ltd is a Japanese company specialized in the development and marketing of innovative medications. It has a long history, being founded in 1717. Originally, it was a Chinese medicine business, but since its establishment in 1924, Ono Pharmaceutical has focused on the development of modern medications. The company's business model is based on research and development of medications. Ono Pharmaceutical has several branches in different countries and works closely with research institutions and universities to develop groundbreaking medications. The company is committed to providing innovative therapies to patients worldwide. Ono Pharmaceutical specializes in several areas, including oncology, immunology, neurology, and diabetes. In oncology, the company has launched several medications, including Opdivo and Sprycel, used for the treatment of various forms of cancer. Opdivo is an immunooncological medication that shows great promise and is used worldwide. In immunology, Ono Pharmaceutical has developed a range of medications, including Nivolumab, used for the treatment of various autoimmune diseases such as rheumatoid arthritis. Ono Pharmaceutical has also developed medications for influenza and other types of infections. In the field of neurology, the company has developed medications used for pain treatment, including the compound Fauldopamine. Despite the discovery of Fauldopamine, which is considered suitable for pain treatment, no final decision has been made regarding the application of this medication. In diabetes research, Ono Pharmaceutical has developed various medications used for the treatment of diabetes, including Alogliptin and Canagliflozin. These medications help diabetics better control their blood sugar levels and alleviate the symptoms of this disease. Ono Pharmaceutical has also launched numerous products used in different areas, such as Desitin, a cream for the treatment of skin disorders, or Minon, a skincare line. The company places great importance on collaboration and innovation to provide highly effective medications to patients. Ono Pharmaceutical is committed to expanding its presence in the global market and developing further innovative therapies to improve people's lives. Ono Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Ono Pharmaceutical Co's Equity

Ono Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Ono Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Ono Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Ono Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Ono Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Ono Pharmaceutical Co stock

What is the equity of Ono Pharmaceutical Co this year?

Ono Pharmaceutical Co has equity of 792.96 B JPY this year.

What was the equity of Ono Pharmaceutical Co compared to the previous year?

The equity of Ono Pharmaceutical Co has increased/decreased by 20.9% increased compared to the previous year.

What impact does a high equity have on investors of Ono Pharmaceutical Co?

A high equity is advantageous for investors of Ono Pharmaceutical Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Ono Pharmaceutical Co?

A low equity can be a risk for investors of Ono Pharmaceutical Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Ono Pharmaceutical Co affect the company?

An increase in equity of Ono Pharmaceutical Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Ono Pharmaceutical Co affect the company?

A reduction in equity of Ono Pharmaceutical Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Ono Pharmaceutical Co?

Some factors that can affect the equity of Ono Pharmaceutical Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Ono Pharmaceutical Co so important for investors?

The equity of Ono Pharmaceutical Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Ono Pharmaceutical Co take to change the equity?

To change equity, Ono Pharmaceutical Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Ono Pharmaceutical Co pay?

Over the past 12 months, Ono Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 3.6 %. For the coming 12 months, Ono Pharmaceutical Co is expected to pay a dividend of 86.14 JPY.

What is the dividend yield of Ono Pharmaceutical Co?

The current dividend yield of Ono Pharmaceutical Co is 3.6 %.

When does Ono Pharmaceutical Co pay dividends?

Ono Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Ono Pharmaceutical Co?

Ono Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Ono Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 86.14 JPY are expected. This corresponds to a dividend yield of 3.88 %.

In which sector is Ono Pharmaceutical Co located?

Ono Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ono Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ono Pharmaceutical Co from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Ono Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Ono Pharmaceutical Co in the year 2023?

In the year 2023, Ono Pharmaceutical Co distributed 77 JPY as dividends.

In which currency does Ono Pharmaceutical Co pay out the dividend?

The dividends of Ono Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ono Pharmaceutical Co

Our stock analysis for Ono Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ono Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.